The global CNS therapeutics market was valued at USD 127.29 billion in 2025 and is projected to reach USD 285.72 billion by 2035, driven by demand for Alzheimer’s and Parkinson’s treatments. North America held 45% of the market; neurodegenerative diseases were the largest segment. Private investment and trends toward biologics and AI are shaping the sector.
Two recent court decisions impact pharmaceutical trade secret litigation. A U.S. District Court dismissed a lawsuit by PTC Therapeutics against former employees, finding no plausible allegation of misappropriation. Separately, the Federal Circuit ruled that it retains jurisdiction over trade secret claims even after voluntary dismissal of patent claims, providing defendants with a clearer path to appellate review.
Three biotech companies announce significant funding: Korsana Biosciences secures $175 million for neurodegenerative therapies, Kos Biotechnology Partners closes a $123 million life sciences fund, and ParcelBio launches with $13 million to advance mRNA medicines.
Quantitative and functional MRI techniques are gaining traction as biomarkers in neurodegenerative diseases. A consensus statement provides MRI endpoint recommendations for clinical trials in hereditary ataxias like SCA and Friedreich ataxia. Separately, research shows resting-state fMRI can distinguish subtypes of multiple system atrophy and may improve early diagnosis.
The global CNS biomarkers market is projected to reach USD 26.13 billion by 2035, amyloid beta therapeutics USD 26.50 billion, and calcineurin inhibitors USD 20.88 billion. AI integration is driving innovation across all three markets.
Drug repurposing expands the therapeutic applications of existing medications, while repositioning examines drugs that never reached market. In neurodegeneration, the approach is described as a pragmatic shortcut into mid- to late-stage trials.
The United Arab Emirates has unveiled two gene therapy projects targeting autism, epilepsy, and rare brain disorders in children. The initiatives focus on underlying genetic causes and earlier diagnosis.
A Johns Hopkins study found GLP-1 users face increased dementia risk after a decade, possibly due to longer lifespan. A separate JCI review found GLP-1 drugs show neuroprotective signals in preclinical studies but consistent cognitive benefits in humans remain unproven.
Genomic technologies including whole-genome sequencing and polygenic risk scores are advancing precision medicine for neurodegenerative diseases like Alzheimer's and Parkinson's. Research reveals complex gene interactions in conditions like PTEN hamartoma tumor syndrome and sex-specific metabolic signatures in Alzheimer's disease. The integration of genomics with molecular neurobiology offers potential for more accurate diagnosis and treatment.
NICE has upheld appeals to review its guidance on Alzheimer's drugs lecanemab and donanemab, sending the decision back to committee. The manufacturers argued NICE failed to account for the treatments' wider impact on unpaid carers. This comes amid broader challenges in neurodegenerative disease research following recent high-profile clinical trial failures.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07758114 |
Prenatal Education on Environmental Exposures During Pregnancy Study (PEEPS) |
RECRUITING | NA |
| NCT07748013 |
Impact of Harp Therapy on Behavioral Disorders in Nursing Home Residents With Neurodegenerative Disease (ARPE) |
COMPLETED | |
| NCT07545473 |
Retinal Hyperspectral Imaging in Neurodegenerative Diseases |
RECRUITING | NA |
| NCT07514520 |
Decision-making, Ethical Consent, and Interactive Dialogue in Ongoing Neurocognitive Decline - DECISION |
ACTIVE_NOT_RECRUITING | |
| NCT07489898 |
Novel Technologies to Measure Vision-related Quality of Life |
NOT_YET_RECRUITING | |
| NCT07470710 |
Study on the Application of ¹⁸F-FCOB04, a MAO-B Targeted PET Imaging Agent, in Neurodegenerative Diseases |
NOT_YET_RECRUITING | EARLY_PHASE1 |
| NCT07324330 |
Slowing Cognitive Decline in Alpha-synucleinopathies by Enhancing Physical Activity |
RECRUITING | NA |
| NCT07268079 |
Validation of the VIRADIA App for Neurological and Cognitive Diagnostics in Virtual Reality |
RECRUITING | |
| NCT07232147 |
Clinical Research on Stem Cell Therapy for Parkinson's Disease |
NOT_YET_RECRUITING | PHASE1 |
| NCT07118137 |
Memory Deterioration in Alzheimer Disease |
RECRUITING |
